Luye Pharma Group

2186 · HKEX · China

Public Market Listing

2186HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Luye Pharma Group are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(12 total)
12Total Assets
4Approved
4Phase 3 / Filed
4Phase 1–2 / Early
9Diseases
Quick filter:
Showing 12 of 12 assets
Target & Modality
Approved
Alkylating DrugSmall molecule
Small Cell Lung Cancer
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
Schizophrenia
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder
Phase 3
Serotonin/norepinephrine/dopamine transporterSmall molecule
Major Depressive Disorder
Evogliptin(Suganon)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
LY01008No recent activity
Phase 3
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerColorectal Cancer
Rotigotine (LY03003)(Jinyouping)No recent activity
Phase 3
Dopamine receptorsSmall molecule
Parkinson's Disease
Phase 2
Serotonin 5-HT2A receptor (antagonist / inverse agonist) · 5-HT2A/5-HT2C · 5-HT2A/2C receptorSmall molecule
Alzheimer's DiseaseParkinson's DiseaseSchizophrenia
Phase 2
5-HT2C/TAAR1 receptorSmall molecule
Alzheimer's DiseaseSchizophrenia
Phase 1
Norepinephrine/dopamine transporter + GABA-A receptorSmall molecule
Major Depressive Disorder
Rotigotine (LY03009)No recent activity
Phase 1
dopamineSmall molecule
Parkinson's Disease

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
December 2027 (2)
LY03020Phase 2Schizophrenia
Est. primary completion 2027-12-31 · NCT07396870 · CT.gov ↗
What to watch
LurbinectedinPhase 3Relapsed Small Cell Lung Cancer
Est. primary completion 2027-12-31 · NCT06496048 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
LurbinectedinPhase 1/2Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Est. primary completion 2028-01-28 · NCT05734066 · CT.gov ↗
What to watch
2029 (2)
August 2029 (2)
LurbinectedinPhase 2Extensive-stage Small-cell Lung Cancer
Est. primary completion 2029-08-04 · NCT07459634 · CT.gov ↗
What to watch
LurbinectedinPhase 3Leiomyosarcoma
Est. primary completion 2029-08-30 · NCT06088290 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 September 2026WithdrawalLurbinectedin (Zepzelca)FDA approves voluntary withdrawal of the Zepzelca second-line SCLC accelerated approval indication
US, FDA · Jazz Pharmaceuticals Ireland, Ltd. · Source ↗
June 2026Topline resultLurbinectedinPhase 3 LAGOON did not meet its overall survival primary endpoint
8 January 2026Topline resultAnsofaxine hydrochlorideRuoxinlin GAD Phase 3 (NCT05970510) reported positive; results support the China NDA
Luye Pharma Group · Source ↗
7 October 2025FDA action dateLurbinectedinPDUFA date set for Zepzelca plus atezolizumab
US, FDA · Source ↗
2 October 2025ApprovalLurbinectedinFDA approves Zepzelca plus atezolizumab as first-line maintenance for ES-SCLC
US, FDA · Source ↗
10 June 2025Filing acceptedLurbinectedinFDA accepts sNDA for Zepzelca plus atezolizumab
US, FDA · Source ↗
10 June 2025Priority reviewLurbinectedinFDA grants Priority Review to Zepzelca plus atezolizumab sNDA
US, FDA · Source ↗

Financial reports

Quarterly & interim (2)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$439M———report ↗

Luye Pharma reported interim 2025-H1 revenue of RMB3.181 billion, up 3.46% YoY, with the structured financial row listing revenue of $438.93M. Profit attributable to owners of the parent company was RMB313 million, down 19.33% YoY, with EPS of 8.32 cents. R&D spend and cash position were not disclosed for the period, though prior-year R&D spend was $38.92M.

The group noted its major products hold competitive positions in oncology, CNS, cardiovascular, and metabolism in China, where IQVIA ranked these as the first, second, fourth, and fifth largest pharmaceutical markets. By treatment area, oncology revenue rose 13.5% to RMB1.295 billion, CNS revenue grew 5.4% to RMB868 million, cardiovascular revenue declined 9.2% to RMB693 million, and metabolism revenue fell 7.9% to RMB180 million. The group also detailed its China and international product portfolios, with international offerings focused on CNS, and stated its 18 major products are expected to see steady or maintained market share.

View 1 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-H1—$39M——report ↗

Annual history (3 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$878M———report ↗
View 2 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$844M$260M——report ↗
2023-FY$869M$83M$456M—report ↗